- Home
- BASE vs OCS Comparison
BASE vs OCS Comparison
Compare BASE & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BASE
- OCS
- Stock Information
- Founded
- BASE 2011
- OCS 2003
- Country
- BASE United States
- OCS Switzerland
- Employees
- BASE N/A
- OCS N/A
- Industry
- BASE EDP Services
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- BASE Technology
- OCS Health Care
- Exchange
- BASE Nasdaq
- OCS Nasdaq
- Market Cap
- BASE 834.0M
- OCS 706.3M
- IPO Year
- BASE 2021
- OCS N/A
- Fundamental
- Price
- BASE $19.25
- OCS $14.14
- Analyst Decision
- BASE Buy
- OCS Strong Buy
- Analyst Count
- BASE 13
- OCS 5
- Target Price
- BASE $23.31
- OCS $29.20
- AVG Volume (30 Days)
- BASE 261.2K
- OCS 73.4K
- Earning Date
- BASE 12-03-2024
- OCS 11-07-2024
- Dividend Yield
- BASE N/A
- OCS N/A
- EPS Growth
- BASE N/A
- OCS N/A
- EPS
- BASE N/A
- OCS N/A
- Revenue
- BASE $198,818,000.00
- OCS $1,027,571.00
- Revenue This Year
- BASE $17.65
- OCS $4.38
- Revenue Next Year
- BASE $15.17
- OCS $905.09
- P/E Ratio
- BASE N/A
- OCS N/A
- Revenue Growth
- BASE 21.00
- OCS N/A
- 52 Week Low
- BASE $13.53
- OCS $9.60
- 52 Week High
- BASE $32.00
- OCS $18.00
- Technical
- Relative Strength Index (RSI)
- BASE 69.59
- OCS 37.01
- Support Level
- BASE $15.65
- OCS $16.44
- Resistance Level
- BASE $20.11
- OCS $18.00
- Average True Range (ATR)
- BASE 0.60
- OCS 0.68
- MACD
- BASE 0.26
- OCS -0.46
- Stochastic Oscillator
- BASE 80.74
- OCS 3.50
About BASE Couchbase Inc.
Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.